SCHEMBL30050112

SCHEMBL30050112

O=C1OCCN1c1ccc(S(=O)(=O)N2CCC3(CCN(Cc4cc(F)ccc4F)CC3)C2)cn1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ SPR P35270 1/20 0.38
▸ GRM5 P41594 4/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ KCNH2 Q12809 3/20 0.36
▸ SSTR5 P35346 2/20 0.36
▸ KCNJ1 P48048 4/20 0.35
▸ CYP2D6 P10635 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ HTR2A P28223 2/20 0.34
▸ HTR2C P28335 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27162170 1.00 ALDH1A1 (0.38) ALDH1A1LMNASMN1; SMN2SPRGRM5
SCHEMBL30050705 0.96 CYP3A4 (0.40) ALDH1A1LMNASMN1; SMN2SPRGRM5
SCHEMBL27162324 0.96 CYP3A4 (0.40) ALDH1A1LMNASMN1; SMN2SPRGRM5
SCHEMBL30049321 0.95 ALDH1A1 (0.41) ALDH1A1LMNASMN1; SMN2GRM5L3MBTL1
SCHEMBL27161719 0.95 ALDH1A1 (0.41) ALDH1A1LMNASMN1; SMN2GRM5L3MBTL1
SCHEMBL30050026 0.91 CYP3A4 (0.44) ALDH1A1LMNASMN1; SMN2SPRGRM5
SCHEMBL27161544 0.91 CYP3A4 (0.44) ALDH1A1LMNASMN1; SMN2SPRGRM5
SCHEMBL30049542 0.90 SMN1; SMN2 (0.40) ALDH1A1LMNASMN1; SMN2L3MBTL1KCNH2
SCHEMBL27162591 0.90 SMN1; SMN2 (0.40) ALDH1A1LMNASMN1; SMN2L3MBTL1KCNH2
SCHEMBL30050073 0.86 CYP3A4 (0.43) ALDH1A1LMNASMN1; SMN2L3MBTL1KCNJ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US claimed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP claimed
WO-2022229405-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-11-03 — — WO claimed
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US disclosed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP disclosed
WO-2022229405-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands SIGMAR1, TMEM97, OPRD1 ALDH1A1 1011/4885LMNA 4086/4885SMN1; SMN2 3118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback